Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients-Reference-Cited by-同舟云学术

Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients

Published:2016-09-13 Issue:6 Volume:82 Page:1528-1538
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Moltó José¹²,Estévez Javier A.³⁴,Miranda Cristina¹²,Cedeño Samandhy⁵,Clotet Bonaventura¹²⁵,Valle Marta³⁴

Affiliation:

1. ‘Lluita contra la Sida’ Foundation, HIV Unit; Hospital Universitari Germans Trias i Pujol; Badalona Spain

2. Department de Medicina; Universitat Autònoma de Barcelona; Barcelona Spain

3. Pharmacokinetic/Pharmacodynamic Modeling and Simulation CIM-St Pau.; Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau-IIB Sant Pau; Barcelona Spain

4. Departament de Farmacologia, de Terapèutica i de Toxicologia; Universitat Autònoma de Barcelona; Barcelona Spain

5. ‘IrsiCaixa’ Foundation, HIV Unit; Hospital Universitari Germans Trias i Pujol; Badalona Spain

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13072/fullpdf

Reference49 articles.

1. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study;Molina;J Acquir Immune Defic Syndr,2010

2. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States;Broder;J Med Econ,2011

3. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study;Zhu;J Antimicrob Chemother,2012

4. Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden;Thuresson;Scand J Infect Dis,2011

5. 96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients;Malan;J Int Assoc Physicians AIDS Care (Chic),2010

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic Drug-Drug Interactions Involving Antiretroviral Agents: An Update;Current Drug Metabolism;2023-07

2. Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients;Expert Review of Clinical Pharmacology;2021-11-26

3. The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV;Expert Opinion on Drug Metabolism & Toxicology;2021-04-29

4. Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients;International Journal of Antimicrobial Agents;2017-03